Swiss-based GlycoEra AG has completed an oversubscribed USD 130 million Series B financing, led by Novo Holdings with participation from Catalio Capital Management, LifeArc Ventures, QIA and Sofinnova Partners, to advance its first-in-class IgG4-targeting extracellular protein degrader GE8820 through clinical proof-of-concept. The company's bispecific degraders uniquely target extracellular and membrane proteins via engineered glycosylation, leveraging natural clearance mechanisms for precise degradation without systemic off-target effects, with lead candidate GE8820 demonstrating potent IgG4 clearance in pre-clinical models of pemphigus vulgaris, MuSK myasthenia gravis and other autoimmune diseases ahead of planned first-in-human trials later this year.